| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 121 | 2024 | 1292 | 26.880 |
Why?
|
| Heart Transplantation | 179 | 2023 | 3301 | 18.410 |
Why?
|
| Heart Failure | 279 | 2024 | 11879 | 16.310 |
Why?
|
| Graft Rejection | 55 | 2023 | 4492 | 4.030 |
Why?
|
| Tissue Donors | 24 | 2023 | 2382 | 3.450 |
Why?
|
| Ventricular Function, Left | 35 | 2024 | 3941 | 2.830 |
Why?
|
| Tissue and Organ Procurement | 9 | 2023 | 986 | 2.690 |
Why?
|
| Heart-Lung Transplantation | 8 | 2020 | 87 | 2.390 |
Why?
|
| Lung Transplantation | 17 | 2023 | 1309 | 2.370 |
Why?
|
| Ventricular Dysfunction, Left | 26 | 2024 | 2145 | 2.350 |
Why?
|
| Heart Ventricles | 25 | 2021 | 3840 | 2.310 |
Why?
|
| Prosthesis Design | 19 | 2024 | 2126 | 2.100 |
Why?
|
| Stroke | 29 | 2024 | 9756 | 2.040 |
Why?
|
| Hemodynamics | 31 | 2024 | 4199 | 1.920 |
Why?
|
| Equipment Failure | 7 | 2020 | 585 | 1.920 |
Why?
|
| Societies, Medical | 16 | 2020 | 3967 | 1.900 |
Why?
|
| Immunosuppressive Agents | 25 | 2021 | 4207 | 1.880 |
Why?
|
| Humans | 541 | 2024 | 768887 | 1.800 |
Why?
|
| Prosthesis Implantation | 7 | 2024 | 594 | 1.780 |
Why?
|
| Paintings | 3 | 2019 | 103 | 1.720 |
Why?
|
| Thrombosis | 17 | 2024 | 2956 | 1.670 |
Why?
|
| Mycophenolic Acid | 10 | 2018 | 348 | 1.660 |
Why?
|
| Waiting Lists | 8 | 2021 | 779 | 1.640 |
Why?
|
| Cardiology | 21 | 2023 | 1701 | 1.630 |
Why?
|
| Heart Failure, Systolic | 6 | 2023 | 134 | 1.590 |
Why?
|
| Anticoagulants | 13 | 2024 | 4850 | 1.550 |
Why?
|
| Heart Diseases | 9 | 2022 | 2819 | 1.530 |
Why?
|
| Postoperative Complications | 29 | 2020 | 15889 | 1.510 |
Why?
|
| Registries | 31 | 2024 | 8384 | 1.430 |
Why?
|
| Natriuretic Peptide, Brain | 20 | 2022 | 1751 | 1.360 |
Why?
|
| Treatment Outcome | 93 | 2024 | 65485 | 1.320 |
Why?
|
| Mitral Valve Insufficiency | 8 | 2020 | 1415 | 1.310 |
Why?
|
| Patient Selection | 22 | 2023 | 4265 | 1.290 |
Why?
|
| Organ Transplantation | 6 | 2020 | 1178 | 1.250 |
Why?
|
| Stroke Volume | 42 | 2024 | 5621 | 1.240 |
Why?
|
| Defibrillators, Implantable | 14 | 2021 | 1498 | 1.210 |
Why?
|
| Coronavirus | 2 | 2020 | 156 | 1.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 16 | 2020 | 3253 | 1.130 |
Why?
|
| Osteolysis | 2 | 2019 | 274 | 1.110 |
Why?
|
| Hypertension, Pulmonary | 11 | 2018 | 1600 | 1.090 |
Why?
|
| Coronary Disease | 24 | 2018 | 5919 | 1.080 |
Why?
|
| Coronavirus Infections | 15 | 2020 | 3116 | 1.060 |
Why?
|
| Hospitalization | 22 | 2024 | 10845 | 1.020 |
Why?
|
| Thromboembolism | 6 | 2024 | 1004 | 1.010 |
Why?
|
| Pneumonia, Viral | 15 | 2020 | 3239 | 1.010 |
Why?
|
| Disease Management | 8 | 2021 | 2537 | 0.980 |
Why?
|
| Middle Aged | 199 | 2024 | 223740 | 0.960 |
Why?
|
| Tacrolimus | 10 | 2021 | 750 | 0.940 |
Why?
|
| Prosthesis Failure | 6 | 2020 | 1209 | 0.920 |
Why?
|
| Prognosis | 62 | 2023 | 30044 | 0.910 |
Why?
|
| Tunica Intima | 13 | 2006 | 459 | 0.910 |
Why?
|
| Male | 230 | 2024 | 365249 | 0.890 |
Why?
|
| Pulmonary Artery | 8 | 2022 | 1945 | 0.880 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2023 | 1483 | 0.880 |
Why?
|
| Hypothyroidism | 2 | 2019 | 668 | 0.880 |
Why?
|
| Shock, Cardiogenic | 4 | 2022 | 711 | 0.870 |
Why?
|
| Cardiovascular Agents | 8 | 2023 | 849 | 0.840 |
Why?
|
| Equipment Design | 9 | 2020 | 3529 | 0.840 |
Why?
|
| Angiotensins | 1 | 2023 | 141 | 0.820 |
Why?
|
| Assisted Circulation | 4 | 2020 | 100 | 0.810 |
Why?
|
| Hyperlipidemias | 6 | 2018 | 773 | 0.800 |
Why?
|
| Cardiotonic Agents | 9 | 2023 | 544 | 0.800 |
Why?
|
| Female | 223 | 2024 | 397464 | 0.780 |
Why?
|
| Coronary Artery Disease | 20 | 2023 | 6569 | 0.780 |
Why?
|
| Exercise Test | 13 | 2020 | 2187 | 0.770 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2022 | 275 | 0.750 |
Why?
|
| Aspirin | 8 | 2023 | 3135 | 0.740 |
Why?
|
| Directed Tissue Donation | 1 | 2021 | 18 | 0.740 |
Why?
|
| Aged | 146 | 2024 | 171790 | 0.730 |
Why?
|
| von Willebrand Factor | 3 | 2019 | 680 | 0.710 |
Why?
|
| Oxygenators, Membrane | 1 | 2020 | 57 | 0.710 |
Why?
|
| Coronary Vessels | 15 | 2018 | 3124 | 0.710 |
Why?
|
| Time Factors | 46 | 2024 | 40266 | 0.710 |
Why?
|
| Pandemics | 19 | 2023 | 8745 | 0.710 |
Why?
|
| von Willebrand Diseases | 2 | 2019 | 135 | 0.700 |
Why?
|
| Myocardial Infarction | 19 | 2023 | 11521 | 0.700 |
Why?
|
| Ventricular Dysfunction, Right | 8 | 2024 | 644 | 0.700 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2021 | 146 | 0.700 |
Why?
|
| Prospective Studies | 75 | 2024 | 54950 | 0.700 |
Why?
|
| Danazol | 1 | 2020 | 44 | 0.690 |
Why?
|
| Internationality | 4 | 2018 | 1008 | 0.690 |
Why?
|
| State Medicine | 1 | 2021 | 219 | 0.690 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2020 | 223 | 0.680 |
Why?
|
| Vitamin K | 2 | 2019 | 314 | 0.670 |
Why?
|
| Platelet Aggregation Inhibitors | 11 | 2023 | 2763 | 0.670 |
Why?
|
| Exercise Therapy | 5 | 2019 | 938 | 0.660 |
Why?
|
| Ventricular Remodeling | 7 | 2016 | 1282 | 0.660 |
Why?
|
| Brain Death | 4 | 2023 | 359 | 0.650 |
Why?
|
| Risk Factors | 59 | 2023 | 74971 | 0.650 |
Why?
|
| Cardiovascular Diseases | 14 | 2022 | 15662 | 0.650 |
Why?
|
| Tricuspid Atresia | 1 | 2019 | 37 | 0.650 |
Why?
|
| Palliative Care | 5 | 2021 | 3644 | 0.640 |
Why?
|
| Mitral Valve | 4 | 2020 | 1475 | 0.640 |
Why?
|
| Cardiac Pacing, Artificial | 8 | 2010 | 881 | 0.630 |
Why?
|
| Guideline Adherence | 13 | 2018 | 2240 | 0.630 |
Why?
|
| Transplantation, Homologous | 23 | 2011 | 4835 | 0.630 |
Why?
|
| Endotoxemia | 1 | 2020 | 198 | 0.620 |
Why?
|
| Myocarditis | 3 | 2020 | 803 | 0.620 |
Why?
|
| Clinical Trials as Topic | 18 | 2021 | 8055 | 0.620 |
Why?
|
| Warfarin | 4 | 2024 | 1493 | 0.620 |
Why?
|
| Sirolimus | 4 | 2013 | 1540 | 0.620 |
Why?
|
| Hepatitis C | 5 | 2022 | 1595 | 0.610 |
Why?
|
| Turtles | 1 | 2018 | 40 | 0.600 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 577 | 0.600 |
Why?
|
| Factor Xa | 1 | 2019 | 166 | 0.600 |
Why?
|
| Bell Palsy | 1 | 2018 | 39 | 0.600 |
Why?
|
| Recovery of Function | 8 | 2023 | 2990 | 0.600 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 350 | 0.600 |
Why?
|
| Graft Survival | 14 | 2023 | 3888 | 0.590 |
Why?
|
| Pulmonary Atresia | 1 | 2019 | 159 | 0.590 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2017 | 44 | 0.580 |
Why?
|
| Adult | 112 | 2024 | 223818 | 0.580 |
Why?
|
| Terminology as Topic | 4 | 2013 | 1541 | 0.570 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 1206 | 0.570 |
Why?
|
| Goals | 2 | 2020 | 716 | 0.570 |
Why?
|
| Antibodies | 3 | 2023 | 2422 | 0.570 |
Why?
|
| Famous Persons | 1 | 2018 | 109 | 0.570 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 13 | 2020 | 1514 | 0.570 |
Why?
|
| Quality of Life | 18 | 2023 | 13510 | 0.560 |
Why?
|
| Resource Allocation | 1 | 2019 | 354 | 0.560 |
Why?
|
| Myocardium | 17 | 2021 | 4790 | 0.560 |
Why?
|
| Incidence | 20 | 2024 | 21545 | 0.560 |
Why?
|
| Cocaine-Related Disorders | 1 | 2020 | 461 | 0.560 |
Why?
|
| Models, Cardiovascular | 2 | 2018 | 983 | 0.560 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2019 | 262 | 0.560 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2665 | 0.550 |
Why?
|
| Endocardium | 8 | 2021 | 249 | 0.550 |
Why?
|
| Hyperammonemia | 1 | 2017 | 80 | 0.550 |
Why?
|
| Chemoprevention | 1 | 2019 | 326 | 0.550 |
Why?
|
| International Normalized Ratio | 5 | 2024 | 382 | 0.540 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 497 | 0.540 |
Why?
|
| Patient Care Team | 2 | 2020 | 2527 | 0.540 |
Why?
|
| Hemoptysis | 1 | 2017 | 152 | 0.530 |
Why?
|
| Ambulatory Care | 17 | 2018 | 2783 | 0.530 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 865 | 0.530 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 1880 | 0.530 |
Why?
|
| Cardiac Output | 2 | 2018 | 838 | 0.530 |
Why?
|
| Magnetics | 1 | 2019 | 599 | 0.520 |
Why?
|
| Survival Rate | 27 | 2022 | 12873 | 0.520 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 220 | 0.520 |
Why?
|
| Cyclosporine | 12 | 2006 | 777 | 0.520 |
Why?
|
| Postoperative Care | 4 | 2024 | 1481 | 0.520 |
Why?
|
| Oxygen Consumption | 9 | 2021 | 1883 | 0.510 |
Why?
|
| Blood Pressure | 14 | 2020 | 8541 | 0.510 |
Why?
|
| Dyspnea | 4 | 2018 | 1352 | 0.510 |
Why?
|
| Health Care Costs | 3 | 2021 | 3270 | 0.500 |
Why?
|
| Cardiomyopathy, Restrictive | 2 | 2006 | 61 | 0.500 |
Why?
|
| Financing, Government | 1 | 2018 | 473 | 0.490 |
Why?
|
| Oxidative Stress | 5 | 2020 | 3138 | 0.480 |
Why?
|
| Brain Ischemia | 5 | 2023 | 3008 | 0.480 |
Why?
|
| Fatty Acids, Monounsaturated | 6 | 1994 | 190 | 0.480 |
Why?
|
| Follow-Up Studies | 40 | 2022 | 39394 | 0.470 |
Why?
|
| Bed Rest | 1 | 2015 | 83 | 0.470 |
Why?
|
| Cause of Death | 8 | 2020 | 3721 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 24 | 2021 | 10397 | 0.470 |
Why?
|
| Fish Oils | 3 | 2009 | 483 | 0.470 |
Why?
|
| Reoperation | 10 | 2023 | 4342 | 0.470 |
Why?
|
| United States | 49 | 2024 | 73180 | 0.460 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 682 | 0.460 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 877 | 0.450 |
Why?
|
| Euthanasia, Passive | 1 | 2014 | 64 | 0.450 |
Why?
|
| Drug Approval | 2 | 2020 | 820 | 0.450 |
Why?
|
| Arteriovenous Malformations | 1 | 2017 | 396 | 0.440 |
Why?
|
| Drug Therapy, Combination | 14 | 2020 | 6320 | 0.440 |
Why?
|
| Cardiac Output, Low | 4 | 2006 | 192 | 0.440 |
Why?
|
| Heart Failure, Diastolic | 1 | 2014 | 77 | 0.440 |
Why?
|
| Atrial Natriuretic Factor | 4 | 2004 | 350 | 0.440 |
Why?
|
| Poliomyelitis | 3 | 2001 | 91 | 0.430 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3580 | 0.430 |
Why?
|
| Medicaid | 2 | 2018 | 2843 | 0.430 |
Why?
|
| Extracorporeal Circulation | 1 | 2013 | 181 | 0.430 |
Why?
|
| Echocardiography | 14 | 2020 | 5046 | 0.420 |
Why?
|
| Drug Combinations | 4 | 2023 | 2088 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 19 | 2019 | 7460 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2022 | 6546 | 0.420 |
Why?
|
| Gene Expression Profiling | 9 | 2010 | 9549 | 0.420 |
Why?
|
| Advance Care Planning | 1 | 2020 | 698 | 0.410 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 417 | 0.410 |
Why?
|
| Life Support Care | 1 | 2014 | 226 | 0.410 |
Why?
|
| Tetrazoles | 4 | 2023 | 923 | 0.410 |
Why?
|
| Risk Assessment | 26 | 2024 | 24330 | 0.410 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2007 | 856 | 0.400 |
Why?
|
| Journal Impact Factor | 1 | 2013 | 156 | 0.400 |
Why?
|
| Hypertension | 17 | 2013 | 8615 | 0.390 |
Why?
|
| Standard of Care | 2 | 2015 | 570 | 0.390 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 954 | 0.390 |
Why?
|
| Urban Population | 7 | 2021 | 2045 | 0.390 |
Why?
|
| Biphenyl Compounds | 3 | 2023 | 1026 | 0.380 |
Why?
|
| Population Dynamics | 1 | 2014 | 314 | 0.380 |
Why?
|
| Calcium Channel Blockers | 7 | 2010 | 691 | 0.380 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 1423 | 0.380 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2017 | 944 | 0.380 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 2008 | 0.380 |
Why?
|
| Heart | 11 | 2023 | 4448 | 0.370 |
Why?
|
| Antitubercular Agents | 2 | 2017 | 1397 | 0.370 |
Why?
|
| Monitoring, Physiologic | 2 | 2023 | 1796 | 0.370 |
Why?
|
| Renin-Angiotensin System | 6 | 2020 | 736 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2020 | 1568 | 0.370 |
Why?
|
| Coronary Circulation | 3 | 2006 | 1617 | 0.360 |
Why?
|
| Natriuretic Agents | 3 | 2007 | 57 | 0.360 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 1001 | 0.360 |
Why?
|
| C-Reactive Protein | 6 | 2005 | 3858 | 0.360 |
Why?
|
| Forecasting | 9 | 2022 | 2946 | 0.360 |
Why?
|
| Edema | 3 | 2020 | 766 | 0.360 |
Why?
|
| Myocardial Contraction | 4 | 2014 | 1526 | 0.350 |
Why?
|
| Blood Vessels | 3 | 2016 | 1110 | 0.350 |
Why?
|
| Drugs, Generic | 2 | 2021 | 455 | 0.350 |
Why?
|
| Vasodilator Agents | 5 | 2020 | 990 | 0.350 |
Why?
|
| Acetylcysteine | 1 | 2011 | 262 | 0.350 |
Why?
|
| Body Composition | 3 | 2016 | 2461 | 0.350 |
Why?
|
| Hypercholesterolemia | 7 | 2006 | 1145 | 0.350 |
Why?
|
| Inflammation | 8 | 2022 | 10869 | 0.350 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2009 | 1399 | 0.340 |
Why?
|
| Hepacivirus | 5 | 2022 | 1344 | 0.340 |
Why?
|
| Self Medication | 1 | 2010 | 115 | 0.340 |
Why?
|
| Smoke | 1 | 2011 | 236 | 0.330 |
Why?
|
| International Agencies | 3 | 2015 | 244 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2021 | 2258 | 0.330 |
Why?
|
| Posture | 2 | 2013 | 957 | 0.330 |
Why?
|
| Drug Administration Schedule | 9 | 2020 | 4862 | 0.330 |
Why?
|
| Biopsy | 14 | 2021 | 6805 | 0.330 |
Why?
|
| Nonprescription Drugs | 1 | 2010 | 119 | 0.320 |
Why?
|
| Cardiomyopathies | 6 | 2019 | 2057 | 0.320 |
Why?
|
| Blood Coagulation Factors | 2 | 2024 | 371 | 0.320 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 1300 | 0.320 |
Why?
|
| Biomedical Research | 5 | 2016 | 3463 | 0.320 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2024 | 1126 | 0.320 |
Why?
|
| Double-Blind Method | 16 | 2023 | 12469 | 0.320 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2018 | 1243 | 0.320 |
Why?
|
| Antihypertensive Agents | 7 | 2020 | 2026 | 0.310 |
Why?
|
| Retrospective Studies | 42 | 2023 | 81892 | 0.310 |
Why?
|
| Europe | 4 | 2023 | 3441 | 0.310 |
Why?
|
| Algorithms | 6 | 2021 | 14199 | 0.310 |
Why?
|
| Antiviral Agents | 5 | 2022 | 3069 | 0.310 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 61 | 0.310 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2007 | 11 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 5 | 2022 | 1737 | 0.300 |
Why?
|
| Immunization Programs | 2 | 2001 | 267 | 0.300 |
Why?
|
| India | 10 | 2017 | 2325 | 0.300 |
Why?
|
| Cardiac Resynchronization Therapy | 4 | 2015 | 560 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 9 | 2005 | 1524 | 0.300 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 6856 | 0.300 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 553 | 0.290 |
Why?
|
| Diuretics | 6 | 2024 | 614 | 0.290 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15955 | 0.290 |
Why?
|
| Obesity | 14 | 2022 | 13087 | 0.290 |
Why?
|
| Heart Defects, Congenital | 3 | 2018 | 4711 | 0.290 |
Why?
|
| Antioxidants | 2 | 2011 | 1673 | 0.290 |
Why?
|
| Indoles | 6 | 1994 | 1836 | 0.290 |
Why?
|
| Multivariate Analysis | 16 | 2017 | 12093 | 0.290 |
Why?
|
| Evidence-Based Medicine | 12 | 2013 | 3709 | 0.290 |
Why?
|
| Aged, 80 and over | 22 | 2020 | 59738 | 0.280 |
Why?
|
| Survival Analysis | 15 | 2020 | 10115 | 0.280 |
Why?
|
| Syndrome | 6 | 2022 | 3274 | 0.280 |
Why?
|
| Nicotinic Agonists | 1 | 2009 | 266 | 0.280 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2009 | 385 | 0.280 |
Why?
|
| Transplantation Immunology | 4 | 2012 | 537 | 0.280 |
Why?
|
| Blood Pressure Determination | 3 | 2019 | 646 | 0.280 |
Why?
|
| Asia | 2 | 2020 | 629 | 0.280 |
Why?
|
| Anticholesteremic Agents | 4 | 1994 | 972 | 0.280 |
Why?
|
| Terminal Care | 1 | 2019 | 1772 | 0.270 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2019 | 158 | 0.270 |
Why?
|
| Preoperative Care | 6 | 2024 | 2258 | 0.270 |
Why?
|
| Exercise | 5 | 2010 | 5953 | 0.270 |
Why?
|
| Materials Testing | 3 | 2023 | 873 | 0.270 |
Why?
|
| Medical History Taking | 1 | 2010 | 779 | 0.270 |
Why?
|
| Fibrinolytic Agents | 4 | 2024 | 2080 | 0.260 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2003 | 538 | 0.260 |
Why?
|
| Patient Readmission | 8 | 2023 | 3313 | 0.260 |
Why?
|
| Cholesterol, HDL | 3 | 2009 | 1820 | 0.260 |
Why?
|
| Prevalence | 14 | 2015 | 15875 | 0.260 |
Why?
|
| Tuberculosis | 2 | 2013 | 2029 | 0.260 |
Why?
|
| Morbidity | 5 | 2016 | 1757 | 0.250 |
Why?
|
| Predictive Value of Tests | 18 | 2019 | 15471 | 0.250 |
Why?
|
| Sex Factors | 15 | 2018 | 10641 | 0.250 |
Why?
|
| Blood Circulation | 2 | 2019 | 248 | 0.250 |
Why?
|
| Myocardial Revascularization | 5 | 2014 | 796 | 0.250 |
Why?
|
| Bloodletting | 1 | 2005 | 22 | 0.250 |
Why?
|
| Cohort Studies | 29 | 2023 | 41800 | 0.250 |
Why?
|
| Case-Control Studies | 13 | 2023 | 22294 | 0.250 |
Why?
|
| Creatinine | 7 | 2011 | 1917 | 0.250 |
Why?
|
| Arteriosclerosis | 3 | 2002 | 1056 | 0.250 |
Why?
|
| Troponin | 3 | 2014 | 535 | 0.240 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2007 | 489 | 0.240 |
Why?
|
| Homocysteine | 3 | 2005 | 637 | 0.240 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 1241 | 0.240 |
Why?
|
| Immune Tolerance | 1 | 2014 | 2323 | 0.240 |
Why?
|
| Pericarditis, Constrictive | 1 | 2004 | 46 | 0.240 |
Why?
|
| China | 4 | 2020 | 2395 | 0.240 |
Why?
|
| Attitude to Death | 1 | 2007 | 401 | 0.240 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 5176 | 0.230 |
Why?
|
| Electric Countershock | 3 | 2014 | 534 | 0.230 |
Why?
|
| Louisiana | 6 | 2004 | 104 | 0.230 |
Why?
|
| Hemorrhage | 4 | 2023 | 3465 | 0.230 |
Why?
|
| Nicotine | 1 | 2009 | 681 | 0.230 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2007 | 494 | 0.220 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 5375 | 0.220 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 564 | 0.220 |
Why?
|
| Carcinoid Heart Disease | 1 | 2003 | 11 | 0.220 |
Why?
|
| Japan | 3 | 2023 | 1418 | 0.220 |
Why?
|
| Drug Interactions | 5 | 2020 | 1421 | 0.220 |
Why?
|
| Diastole | 4 | 2018 | 784 | 0.220 |
Why?
|
| Pravastatin | 2 | 2002 | 393 | 0.220 |
Why?
|
| Computer Simulation | 2 | 2017 | 6289 | 0.220 |
Why?
|
| Patient Care Planning | 2 | 2020 | 904 | 0.220 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 828 | 0.220 |
Why?
|
| Epoprostenol | 1 | 2004 | 246 | 0.220 |
Why?
|
| Smoking | 4 | 2012 | 9094 | 0.220 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 56 | 0.210 |
Why?
|
| Treatment Failure | 2 | 2018 | 2663 | 0.210 |
Why?
|
| Adhesives | 1 | 2023 | 67 | 0.210 |
Why?
|
| Simvastatin | 2 | 2002 | 346 | 0.210 |
Why?
|
| Administration, Oral | 5 | 2024 | 4042 | 0.210 |
Why?
|
| Piperazines | 2 | 2004 | 2553 | 0.210 |
Why?
|
| Population | 1 | 2003 | 141 | 0.210 |
Why?
|
| Vascular Diseases | 2 | 2010 | 1162 | 0.210 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 4429 | 0.210 |
Why?
|
| Neurotransmitter Agents | 2 | 2006 | 665 | 0.210 |
Why?
|
| Silicones | 1 | 2023 | 228 | 0.210 |
Why?
|
| Sternotomy | 1 | 2024 | 132 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2007 | 1893 | 0.210 |
Why?
|
| Blood Coagulation | 1 | 2009 | 1161 | 0.210 |
Why?
|
| Consensus | 4 | 2024 | 3214 | 0.210 |
Why?
|
| Natriuretic Peptides | 2 | 2023 | 156 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 10778 | 0.200 |
Why?
|
| Diagnosis, Differential | 8 | 2018 | 13020 | 0.200 |
Why?
|
| Thoracotomy | 2 | 2024 | 374 | 0.200 |
Why?
|
| Nutrition Disorders | 1 | 2003 | 204 | 0.200 |
Why?
|
| Rhabdomyolysis | 2 | 2020 | 150 | 0.200 |
Why?
|
| Disease Outbreaks | 2 | 2020 | 1761 | 0.200 |
Why?
|
| Neoplasms | 7 | 2023 | 22390 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 3 | 2014 | 1309 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1151 | 0.200 |
Why?
|
| Outpatients | 7 | 2013 | 1604 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 4 | 2022 | 5544 | 0.200 |
Why?
|
| Comorbidity | 10 | 2020 | 10591 | 0.200 |
Why?
|
| Poverty Areas | 2 | 2004 | 269 | 0.190 |
Why?
|
| Lung Diseases | 4 | 2014 | 1943 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5716 | 0.190 |
Why?
|
| Physicians | 4 | 2024 | 4607 | 0.190 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2122 | 0.190 |
Why?
|
| History, 20th Century | 6 | 2013 | 2771 | 0.190 |
Why?
|
| Ventricular Function, Right | 3 | 2024 | 628 | 0.190 |
Why?
|
| Stress, Mechanical | 2 | 2017 | 1680 | 0.190 |
Why?
|
| Hypotension | 4 | 2018 | 888 | 0.190 |
Why?
|
| Calcineurin | 1 | 2002 | 235 | 0.190 |
Why?
|
| Electrocardiography | 11 | 2021 | 6413 | 0.190 |
Why?
|
| Echocardiography, Doppler | 6 | 2014 | 898 | 0.180 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2000 | 24 | 0.180 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 34 | 0.180 |
Why?
|
| Losartan | 1 | 2002 | 262 | 0.180 |
Why?
|
| Chronic Disease | 9 | 2019 | 9384 | 0.180 |
Why?
|
| Coronary Artery Bypass | 3 | 2023 | 2194 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 1947 | 0.180 |
Why?
|
| Research Design | 8 | 2020 | 6213 | 0.180 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 50 | 0.180 |
Why?
|
| Heart Neoplasms | 1 | 2004 | 374 | 0.180 |
Why?
|
| Thoracoscopy | 1 | 2001 | 186 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 7 | 2022 | 1568 | 0.180 |
Why?
|
| Age Factors | 13 | 2021 | 18454 | 0.180 |
Why?
|
| Esophageal Achalasia | 1 | 2001 | 98 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2019 | 2056 | 0.180 |
Why?
|
| Hospitals, Special | 1 | 2020 | 90 | 0.170 |
Why?
|
| Amiodarone | 1 | 2002 | 217 | 0.170 |
Why?
|
| Isoantibodies | 2 | 2009 | 681 | 0.170 |
Why?
|
| Medicare | 1 | 2018 | 6888 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 3744 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2003 | 407 | 0.170 |
Why?
|
| Neprilysin | 1 | 2023 | 487 | 0.170 |
Why?
|
| Gene Expression | 3 | 2010 | 7602 | 0.170 |
Why?
|
| Organ Specificity | 2 | 2020 | 1970 | 0.170 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 2139 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 1903 | 0.170 |
Why?
|
| Paresis | 1 | 2021 | 177 | 0.170 |
Why?
|
| Genital Diseases, Female | 1 | 2001 | 192 | 0.170 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 412 | 0.170 |
Why?
|
| Immunomodulation | 2 | 2020 | 549 | 0.170 |
Why?
|
| Platelet Count | 1 | 2002 | 787 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2006 | 1813 | 0.170 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 150 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 1064 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 18366 | 0.160 |
Why?
|
| Centrifugation | 1 | 2019 | 122 | 0.160 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2003 | 362 | 0.160 |
Why?
|
| Sexual Behavior | 2 | 2007 | 2200 | 0.160 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2002 | 452 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 232 | 0.160 |
Why?
|
| Catheters | 1 | 2022 | 427 | 0.160 |
Why?
|
| Amyloidosis | 1 | 2006 | 879 | 0.160 |
Why?
|
| Adolescent | 21 | 2020 | 89247 | 0.160 |
Why?
|
| Edema, Cardiac | 1 | 2018 | 19 | 0.160 |
Why?
|
| Transfection | 1 | 2006 | 5763 | 0.160 |
Why?
|
| History, 16th Century | 1 | 2018 | 70 | 0.160 |
Why?
|
| Cachexia | 3 | 2023 | 202 | 0.160 |
Why?
|
| Organ Preservation | 2 | 2023 | 394 | 0.150 |
Why?
|
| Laser Therapy | 3 | 2000 | 1110 | 0.150 |
Why?
|
| Bundle-Branch Block | 3 | 2008 | 278 | 0.150 |
Why?
|
| Body Weight | 3 | 2006 | 4628 | 0.150 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 1998 | 38 | 0.150 |
Why?
|
| Antigens, CD | 2 | 2013 | 4032 | 0.150 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 251 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2022 | 1741 | 0.150 |
Why?
|
| Costs and Cost Analysis | 3 | 2018 | 1669 | 0.150 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 828 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2009 | 2479 | 0.150 |
Why?
|
| Coronary Angiography | 10 | 2018 | 4541 | 0.150 |
Why?
|
| Attitude of Health Personnel | 2 | 2003 | 3925 | 0.150 |
Why?
|
| Alanine | 1 | 2020 | 614 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 775 | 0.150 |
Why?
|
| Carbamates | 1 | 2019 | 192 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 2021 | 435 | 0.140 |
Why?
|
| Death | 2 | 2023 | 683 | 0.140 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 12563 | 0.140 |
Why?
|
| Donor Selection | 1 | 2019 | 240 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3442 | 0.140 |
Why?
|
| Dobutamine | 3 | 2007 | 116 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 941 | 0.140 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 97 | 0.140 |
Why?
|
| Comprehensive Health Care | 1 | 1998 | 123 | 0.140 |
Why?
|
| Heart Rate | 6 | 2023 | 4217 | 0.140 |
Why?
|
| Social Work | 1 | 2018 | 158 | 0.140 |
Why?
|
| Disease Progression | 8 | 2020 | 13677 | 0.140 |
Why?
|
| Electrodes, Implanted | 1 | 2021 | 841 | 0.140 |
Why?
|
| Poisoning | 1 | 2018 | 252 | 0.140 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2002 | 595 | 0.140 |
Why?
|
| Animals | 20 | 2023 | 169408 | 0.140 |
Why?
|
| Laboratories | 1 | 2020 | 463 | 0.130 |
Why?
|
| Italy | 1 | 2018 | 855 | 0.130 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1997 | 213 | 0.130 |
Why?
|
| Systole | 4 | 2003 | 937 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2003 | 1611 | 0.130 |
Why?
|
| Mass Screening | 3 | 2010 | 5455 | 0.130 |
Why?
|
| Aorta | 3 | 2013 | 2046 | 0.130 |
Why?
|
| Eligibility Determination | 2 | 2011 | 421 | 0.130 |
Why?
|
| Heart Function Tests | 2 | 2007 | 317 | 0.130 |
Why?
|
| Young Adult | 7 | 2020 | 60110 | 0.130 |
Why?
|
| Peptide Fragments | 5 | 2022 | 5150 | 0.130 |
Why?
|
| Hospital Restructuring | 1 | 2015 | 11 | 0.130 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 387 | 0.130 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 2231 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 5505 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2010 | 4859 | 0.130 |
Why?
|
| Physician Executives | 1 | 2016 | 140 | 0.120 |
Why?
|
| History, Ancient | 2 | 2006 | 213 | 0.120 |
Why?
|
| Esophagus | 1 | 2001 | 1043 | 0.120 |
Why?
|
| Mortality | 4 | 2021 | 2915 | 0.120 |
Why?
|
| Patient Discharge | 2 | 2023 | 3490 | 0.120 |
Why?
|
| Biomedical Technology | 1 | 2017 | 210 | 0.120 |
Why?
|
| Health Literacy | 1 | 2021 | 467 | 0.120 |
Why?
|
| Placebos | 1 | 2019 | 1668 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2014 | 1141 | 0.120 |
Why?
|
| T-Lymphocytes | 4 | 2010 | 10276 | 0.120 |
Why?
|
| Glucosides | 1 | 2020 | 533 | 0.120 |
Why?
|
| Pyridones | 2 | 1997 | 819 | 0.120 |
Why?
|
| Multigene Family | 2 | 2010 | 1082 | 0.120 |
Why?
|
| Rural Population | 4 | 2021 | 2322 | 0.120 |
Why?
|
| Hemolysis | 1 | 2017 | 417 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2003 | 984 | 0.120 |
Why?
|
| Angiotensin II | 2 | 2017 | 844 | 0.120 |
Why?
|
| Educational Status | 1 | 2002 | 2515 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 5892 | 0.120 |
Why?
|
| Acute Disease | 9 | 2011 | 7245 | 0.120 |
Why?
|
| Body Mass Index | 8 | 2022 | 13054 | 0.120 |
Why?
|
| Health Education | 1 | 2001 | 1059 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 3 | 2011 | 2181 | 0.120 |
Why?
|
| Risk | 4 | 2015 | 9621 | 0.120 |
Why?
|
| Disability Evaluation | 3 | 2019 | 1839 | 0.120 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2017 | 373 | 0.120 |
Why?
|
| Organ Size | 2 | 2019 | 2268 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 1033 | 0.120 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2011 | 1724 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 425 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 732 | 0.110 |
Why?
|
| Cytokines | 7 | 2012 | 7453 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2020 | 1191 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2019 | 968 | 0.110 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 257 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 551 | 0.110 |
Why?
|
| Iron | 1 | 2022 | 1813 | 0.110 |
Why?
|
| Positron-Emission Tomography | 3 | 2021 | 6673 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2014 | 120 | 0.110 |
Why?
|
| Ultrasonography | 9 | 2011 | 6001 | 0.110 |
Why?
|
| Science | 1 | 2016 | 236 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2024 | 8742 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2021 | 2396 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 4926 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2010 | 2493 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 2019 | 535 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2022 | 2395 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2006 | 3538 | 0.110 |
Why?
|
| Milrinone | 3 | 2006 | 86 | 0.110 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 1602 | 0.110 |
Why?
|
| Hemoglobins | 2 | 2009 | 1531 | 0.110 |
Why?
|
| Heart Conduction System | 4 | 2009 | 1009 | 0.110 |
Why?
|
| Genomics | 2 | 2006 | 5928 | 0.110 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 811 | 0.110 |
Why?
|
| Communication | 2 | 2023 | 3908 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 943 | 0.110 |
Why?
|
| Propensity Score | 1 | 2021 | 1968 | 0.100 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 677 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 465 | 0.100 |
Why?
|
| Aorta, Abdominal | 1 | 1996 | 627 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2020 | 635 | 0.100 |
Why?
|
| Quality Improvement | 3 | 2020 | 3856 | 0.100 |
Why?
|
| Medical Futility | 1 | 2014 | 136 | 0.100 |
Why?
|
| Ticlopidine | 2 | 2011 | 730 | 0.100 |
Why?
|
| Health Resources | 1 | 2019 | 951 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 2 | 2011 | 242 | 0.100 |
Why?
|
| France | 2 | 2009 | 497 | 0.100 |
Why?
|
| Epidemics | 1 | 2018 | 517 | 0.100 |
Why?
|
| Recurrence | 4 | 2020 | 8512 | 0.100 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 4265 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2015 | 540 | 0.100 |
Why?
|
| Coronary Care Units | 1 | 2013 | 235 | 0.100 |
Why?
|
| Prothrombin | 2 | 2010 | 194 | 0.100 |
Why?
|
| Databases, Factual | 6 | 2020 | 8095 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2019 | 1585 | 0.100 |
Why?
|
| Resuscitation Orders | 1 | 2014 | 271 | 0.100 |
Why?
|
| Device Removal | 1 | 2017 | 643 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2015 | 548 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 20244 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2019 | 1198 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1672 | 0.100 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2011 | 27 | 0.100 |
Why?
|
| Personal Autonomy | 1 | 2014 | 315 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3814 | 0.090 |
Why?
|
| Natriuresis | 1 | 2011 | 106 | 0.090 |
Why?
|
| Ventricular Function | 3 | 2008 | 406 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2017 | 9682 | 0.090 |
Why?
|
| Hypolipidemic Agents | 3 | 2002 | 609 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2014 | 307 | 0.090 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2011 | 38 | 0.090 |
Why?
|
| Sulfones | 2 | 2004 | 448 | 0.090 |
Why?
|
| Aortic Diseases | 1 | 1997 | 741 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1597 | 0.090 |
Why?
|
| Latin America | 2 | 2021 | 416 | 0.090 |
Why?
|
| Therapeutic Equivalency | 2 | 2009 | 134 | 0.090 |
Why?
|
| Proteins | 1 | 2006 | 6011 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5520 | 0.090 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 812 | 0.090 |
Why?
|
| Heart Block | 2 | 2008 | 390 | 0.090 |
Why?
|
| Cyclohexanes | 1 | 2011 | 152 | 0.090 |
Why?
|
| Cotinine | 1 | 2011 | 206 | 0.090 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2015 | 346 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2017 | 1959 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2004 | 1898 | 0.090 |
Why?
|
| Cholesterol, LDL | 5 | 2004 | 2402 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 1209 | 0.090 |
Why?
|
| Vascular Resistance | 2 | 2004 | 939 | 0.090 |
Why?
|
| Death, Sudden | 2 | 2019 | 301 | 0.090 |
Why?
|
| Coronary Occlusion | 1 | 2013 | 306 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2013 | 1575 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 1998 | 1076 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 325 | 0.090 |
Why?
|
| Purines | 2 | 2004 | 615 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2011 | 153 | 0.090 |
Why?
|
| Advanced Practice Nursing | 1 | 2010 | 18 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 350 | 0.090 |
Why?
|
| Blood Volume | 1 | 2011 | 546 | 0.090 |
Why?
|
| Histocompatibility Testing | 3 | 2006 | 716 | 0.090 |
Why?
|
| Program Evaluation | 2 | 2016 | 2507 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2002 | 4053 | 0.090 |
Why?
|
| Critical Illness | 3 | 2011 | 2754 | 0.090 |
Why?
|
| Triglycerides | 6 | 2004 | 2464 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2277 | 0.090 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 3421 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2012 | 426 | 0.080 |
Why?
|
| Life Style | 1 | 2001 | 3931 | 0.080 |
Why?
|
| Erythropoiesis | 2 | 2010 | 693 | 0.080 |
Why?
|
| Developing Countries | 1 | 2022 | 2906 | 0.080 |
Why?
|
| Immunization Schedule | 2 | 2001 | 228 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 246 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2001 | 2055 | 0.080 |
Why?
|
| Rats | 4 | 2023 | 23847 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 1812 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 1321 | 0.080 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 14751 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2018 | 3683 | 0.080 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 929 | 0.080 |
Why?
|
| Erythrocyte Indices | 1 | 2009 | 143 | 0.080 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2009 | 91 | 0.080 |
Why?
|
| Endothelium, Vascular | 4 | 2020 | 4428 | 0.080 |
Why?
|
| Hyperplasia | 3 | 1997 | 1154 | 0.080 |
Why?
|
| Tachycardia, Sinus | 1 | 2008 | 43 | 0.080 |
Why?
|
| Survivors | 1 | 2019 | 2383 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2015 | 672 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 591 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3436 | 0.080 |
Why?
|
| Encephalitis | 1 | 2012 | 441 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 1177 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 311 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 9264 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2021 | 3626 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2009 | 169 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2002 | 3985 | 0.070 |
Why?
|
| Cholesterol | 5 | 2004 | 2913 | 0.070 |
Why?
|
| Cell Division | 1 | 1995 | 4478 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2003 | 6610 | 0.070 |
Why?
|
| Thioredoxins | 1 | 2009 | 202 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2009 | 279 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 193 | 0.070 |
Why?
|
| Physician Assistants | 1 | 2010 | 190 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2010 | 308 | 0.070 |
Why?
|
| International Cooperation | 2 | 2013 | 1436 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 610 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8559 | 0.070 |
Why?
|
| Bilirubin | 1 | 2009 | 438 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2009 | 331 | 0.070 |
Why?
|
| Dementia | 1 | 2002 | 2741 | 0.070 |
Why?
|
| Morpholines | 1 | 2010 | 584 | 0.070 |
Why?
|
| Heart Septum | 1 | 2008 | 304 | 0.070 |
Why?
|
| Osteopontin | 1 | 2009 | 311 | 0.070 |
Why?
|
| Length of Stay | 4 | 2015 | 6525 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1946 | 0.070 |
Why?
|
| History, 19th Century | 3 | 2005 | 715 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3591 | 0.070 |
Why?
|
| DNA Primers | 1 | 2011 | 2827 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2006 | 44 | 0.070 |
Why?
|
| Probability | 3 | 2009 | 2483 | 0.070 |
Why?
|
| Azathioprine | 2 | 2006 | 354 | 0.070 |
Why?
|
| Platelet Function Tests | 1 | 2009 | 275 | 0.070 |
Why?
|
| Ventricular Dysfunction | 1 | 2007 | 144 | 0.070 |
Why?
|
| Motor Activity | 1 | 2017 | 2722 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1407 | 0.070 |
Why?
|
| Renin | 1 | 2009 | 648 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 299 | 0.070 |
Why?
|
| Quality of Health Care | 3 | 2018 | 4338 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2003 | 5707 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 683 | 0.070 |
Why?
|
| Oxygen | 1 | 2018 | 4273 | 0.070 |
Why?
|
| Pericardial Effusion | 1 | 2008 | 246 | 0.070 |
Why?
|
| Elasticity | 2 | 2006 | 657 | 0.070 |
Why?
|
| Thrombelastography | 1 | 2009 | 194 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 595 | 0.070 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2006 | 44 | 0.070 |
Why?
|
| Cardiography, Impedance | 1 | 2006 | 40 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 1112 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2018 | 2518 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2006 | 389 | 0.070 |
Why?
|
| Thiophenes | 1 | 2010 | 570 | 0.070 |
Why?
|
| Brain | 3 | 2021 | 27476 | 0.060 |
Why?
|
| Primary Prevention | 2 | 2010 | 1187 | 0.060 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 4251 | 0.060 |
Why?
|
| Propanolamines | 1 | 2006 | 164 | 0.060 |
Why?
|
| Proteomics | 3 | 2022 | 3913 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2014 | 1830 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2012 | 12809 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4077 | 0.060 |
Why?
|
| Benzazepines | 1 | 2008 | 309 | 0.060 |
Why?
|
| Longitudinal Studies | 7 | 2014 | 14795 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2003 | 843 | 0.060 |
Why?
|
| Troponin T | 1 | 2010 | 787 | 0.060 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 769 | 0.060 |
Why?
|
| Hydrazones | 1 | 2006 | 105 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 384 | 0.060 |
Why?
|
| Therapeutics | 1 | 2006 | 113 | 0.060 |
Why?
|
| History, 15th Century | 1 | 2005 | 29 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 379 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 2598 | 0.060 |
Why?
|
| History, Medieval | 1 | 2005 | 62 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2015 | 1262 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 2634 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2007 | 615 | 0.060 |
Why?
|
| Peroxidase | 1 | 2008 | 610 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 36861 | 0.060 |
Why?
|
| Physical Examination | 1 | 2011 | 1262 | 0.060 |
Why?
|
| Fluid Therapy | 2 | 2008 | 587 | 0.060 |
Why?
|
| Ventricular Pressure | 1 | 2006 | 210 | 0.060 |
Why?
|
| Ireland | 3 | 2001 | 170 | 0.060 |
Why?
|
| Pediatrics | 2 | 2013 | 3628 | 0.060 |
Why?
|
| Lung | 3 | 2020 | 10097 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1434 | 0.060 |
Why?
|
| Cardiovascular Deconditioning | 1 | 2004 | 9 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 878 | 0.060 |
Why?
|
| Drug Costs | 1 | 2013 | 1198 | 0.060 |
Why?
|
| Nitroglycerin | 1 | 2006 | 332 | 0.060 |
Why?
|
| Carbazoles | 1 | 2006 | 230 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20776 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2006 | 373 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 2203 | 0.060 |
Why?
|
| Western World | 1 | 2004 | 27 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2015 | 2701 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 21187 | 0.060 |
Why?
|
| Mercury | 2 | 2001 | 289 | 0.060 |
Why?
|
| Pyridazines | 1 | 2006 | 203 | 0.060 |
Why?
|
| Public Health | 1 | 2017 | 2680 | 0.060 |
Why?
|
| Health Status | 2 | 2014 | 4095 | 0.060 |
Why?
|
| Organelles | 1 | 2006 | 265 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2005 | 387 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 3 | 2002 | 839 | 0.060 |
Why?
|
| Eye Infections | 1 | 2004 | 62 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 365 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1836 | 0.060 |
Why?
|
| Esophagectomy | 1 | 2008 | 482 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 848 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2931 | 0.060 |
Why?
|
| Adrenergic Antagonists | 1 | 2003 | 26 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2005 | 277 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2007 | 433 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 393 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2012 | 4879 | 0.050 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 2339 | 0.050 |
Why?
|
| Decision Trees | 2 | 2016 | 509 | 0.050 |
Why?
|
| Canada | 1 | 2009 | 2129 | 0.050 |
Why?
|
| Endothelins | 1 | 2003 | 127 | 0.050 |
Why?
|
| Weight Loss | 3 | 2020 | 2720 | 0.050 |
Why?
|
| Ultrasonics | 1 | 2004 | 208 | 0.050 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 2194 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1476 | 0.050 |
Why?
|
| Tachycardia | 1 | 2005 | 599 | 0.050 |
Why?
|
| Artifacts | 1 | 2011 | 1942 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 1601 | 0.050 |
Why?
|
| Cholecystectomy | 2 | 2003 | 409 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2009 | 1600 | 0.050 |
Why?
|
| Policy Making | 1 | 2006 | 546 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 969 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2008 | 971 | 0.050 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 428 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2006 | 1251 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2023 | 395 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 2724 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2006 | 797 | 0.050 |
Why?
|
| Tobacco Use Disorder | 1 | 2008 | 708 | 0.050 |
Why?
|
| Organomercury Compounds | 1 | 2001 | 16 | 0.050 |
Why?
|
| Critical Care | 2 | 2013 | 2715 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 2422 | 0.050 |
Why?
|
| Gallbladder Diseases | 1 | 2003 | 139 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2011 | 1293 | 0.050 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 681 | 0.050 |
Why?
|
| Education, Medical | 1 | 2013 | 1742 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 1470 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2004 | 668 | 0.050 |
Why?
|
| Logistic Models | 3 | 2009 | 13317 | 0.050 |
Why?
|
| Plasmids | 1 | 2006 | 2269 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 1364 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2013 | 2192 | 0.050 |
Why?
|
| Direct Service Costs | 2 | 1998 | 61 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 2004 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2228 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2011 | 2898 | 0.050 |
Why?
|
| Mitochondria, Heart | 1 | 2002 | 236 | 0.050 |
Why?
|
| Hygiene | 1 | 2001 | 95 | 0.050 |
Why?
|
| Child | 7 | 2020 | 80969 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 4356 | 0.040 |
Why?
|
| Fundoplication | 1 | 2001 | 145 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2004 | 2359 | 0.040 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2022 | 199 | 0.040 |
Why?
|
| Biological Assay | 1 | 2003 | 628 | 0.040 |
Why?
|
| Base Sequence | 1 | 2011 | 12430 | 0.040 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 92 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2421 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 1992 | 1936 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 8200 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2005 | 620 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 1738 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 6991 | 0.040 |
Why?
|
| Safety Management | 1 | 2005 | 765 | 0.040 |
Why?
|
| Phentermine | 1 | 1999 | 31 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1999 | 58 | 0.040 |
Why?
|
| Thienopyridines | 1 | 2019 | 9 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2006 | 1895 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2008 | 2357 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2008 | 944 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2006 | 2604 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4593 | 0.040 |
Why?
|
| Counseling | 1 | 2007 | 1554 | 0.040 |
Why?
|
| Anemia | 1 | 2009 | 1516 | 0.040 |
Why?
|
| Contrast Media | 1 | 1992 | 5334 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1320 | 0.040 |
Why?
|
| Demography | 2 | 2020 | 1643 | 0.040 |
Why?
|
| Hospital Mortality | 4 | 2020 | 5369 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2005 | 1142 | 0.040 |
Why?
|
| Body Size | 1 | 2022 | 463 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1999 | 108 | 0.040 |
Why?
|
| Colchicine | 1 | 2020 | 257 | 0.040 |
Why?
|
| Cell Survival | 1 | 2009 | 5794 | 0.040 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2018 | 8 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 151 | 0.040 |
Why?
|
| Attitude | 1 | 2024 | 772 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2003 | 349 | 0.040 |
Why?
|
| Chloroquine | 1 | 2020 | 275 | 0.040 |
Why?
|
| ROC Curve | 1 | 2007 | 3629 | 0.040 |
Why?
|
| Fibrosis | 1 | 2006 | 2081 | 0.040 |
Why?
|
| Medical Records | 3 | 2012 | 1411 | 0.040 |
Why?
|
| Immunization | 1 | 2003 | 1219 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2009 | 3701 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 1209 | 0.040 |
Why?
|
| Intestinal Secretions | 1 | 1998 | 15 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2003 | 633 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1762 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 3 | 2013 | 1515 | 0.040 |
Why?
|
| Kidney | 4 | 2020 | 7057 | 0.040 |
Why?
|
| Hyperhomocysteinemia | 1 | 1998 | 118 | 0.040 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 139 | 0.040 |
Why?
|
| Estrogens | 1 | 2005 | 1537 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2006 | 1812 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 3438 | 0.040 |
Why?
|
| Gemfibrozil | 1 | 1997 | 30 | 0.040 |
Why?
|
| History, 18th Century | 1 | 1998 | 206 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3811 | 0.040 |
Why?
|
| Autonomic Nervous System | 2 | 2000 | 709 | 0.040 |
Why?
|
| Angioscopy | 1 | 1997 | 47 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2003 | 1336 | 0.040 |
Why?
|
| Medical Errors | 1 | 2005 | 1262 | 0.040 |
Why?
|
| Water | 1 | 2023 | 1421 | 0.040 |
Why?
|
| Pressoreceptors | 1 | 1997 | 99 | 0.040 |
Why?
|
| Volition | 1 | 2017 | 61 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2024 | 1279 | 0.030 |
Why?
|
| Anastomosis, Surgical | 2 | 2013 | 994 | 0.030 |
Why?
|
| Crisis Intervention | 1 | 1998 | 111 | 0.030 |
Why?
|
| Regression Analysis | 4 | 2012 | 6346 | 0.030 |
Why?
|
| Dogs | 2 | 2011 | 3845 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2020 | 2560 | 0.030 |
Why?
|
| Pigmentation | 1 | 1997 | 143 | 0.030 |
Why?
|
| Anesthesia | 1 | 2008 | 1596 | 0.030 |
Why?
|
| Resistance Training | 1 | 2019 | 199 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2020 | 503 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2006 | 3335 | 0.030 |
Why?
|
| Endpoint Determination | 2 | 2010 | 594 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2024 | 1045 | 0.030 |
Why?
|
| Autopsy | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2597 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2007 | 2100 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2018 | 365 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2862 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1996 | 175 | 0.030 |
Why?
|
| Infant | 3 | 2020 | 36541 | 0.030 |
Why?
|
| Family Practice | 1 | 1998 | 509 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13593 | 0.030 |
Why?
|
| Reflex | 1 | 1997 | 375 | 0.030 |
Why?
|
| Thyroxine | 1 | 1999 | 665 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 733 | 0.030 |
Why?
|
| Atherectomy, Coronary | 1 | 1995 | 138 | 0.030 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1995 | 55 | 0.030 |
Why?
|
| Vibrio Infections | 1 | 1995 | 33 | 0.030 |
Why?
|
| Condoms | 1 | 1997 | 338 | 0.030 |
Why?
|
| Arteries | 1 | 2000 | 1126 | 0.030 |
Why?
|
| Lisinopril | 1 | 1995 | 60 | 0.030 |
Why?
|
| Platelet Activating Factor | 2 | 1998 | 143 | 0.030 |
Why?
|
| Cell Line | 1 | 2009 | 15603 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 1996 | 175 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1379 | 0.030 |
Why?
|
| Diltiazem | 1 | 1995 | 132 | 0.030 |
Why?
|
| Nifedipine | 1 | 1995 | 220 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2019 | 2871 | 0.030 |
Why?
|
| Elastic Tissue | 1 | 1995 | 66 | 0.030 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1997 | 273 | 0.030 |
Why?
|
| Verapamil | 1 | 1995 | 242 | 0.030 |
Why?
|
| Heart Atria | 1 | 2021 | 1360 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2001 | 1176 | 0.030 |
Why?
|
| Mucins | 1 | 1998 | 571 | 0.030 |
Why?
|
| Captopril | 1 | 1995 | 262 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 11934 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 1994 | 70 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 3269 | 0.030 |
Why?
|
| Complement C3d | 1 | 2013 | 21 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 1997 | 293 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2007 | 3800 | 0.030 |
Why?
|
| Histocompatibility | 1 | 1995 | 321 | 0.030 |
Why?
|
| Research | 1 | 2002 | 1981 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2003 | 2063 | 0.030 |
Why?
|
| Pyridines | 1 | 2006 | 2896 | 0.030 |
Why?
|
| Case Management | 1 | 1995 | 276 | 0.030 |
Why?
|
| beta Carotene | 1 | 1995 | 523 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 1995 | 236 | 0.030 |
Why?
|
| Income | 1 | 2002 | 1878 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 184 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1996 | 435 | 0.030 |
Why?
|
| Rome | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 2660 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2084 | 0.030 |
Why?
|
| Enalapril | 1 | 1995 | 317 | 0.030 |
Why?
|
| Stem Cells | 1 | 2006 | 3540 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1996 | 428 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2006 | 275 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2020 | 42684 | 0.030 |
Why?
|
| Reactive Nitrogen Species | 1 | 2012 | 35 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 888 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 283 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 1998 | 941 | 0.020 |
Why?
|
| Mannitol | 1 | 1992 | 177 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1996 | 1149 | 0.020 |
Why?
|
| Carotenoids | 1 | 1995 | 620 | 0.020 |
Why?
|
| Group Processes | 1 | 2013 | 228 | 0.020 |
Why?
|
| Furosemide | 1 | 1992 | 174 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 1995 | 658 | 0.020 |
Why?
|
| Mental Health | 1 | 2006 | 3275 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3724 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 7956 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 2011 | 957 | 0.020 |
Why?
|
| Liver | 3 | 2020 | 7579 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 26384 | 0.020 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 537 | 0.020 |
Why?
|
| Patient Participation | 1 | 2020 | 1448 | 0.020 |
Why?
|
| Syncope | 1 | 2014 | 430 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 2030 | 0.020 |
Why?
|
| Home Care Services | 1 | 1997 | 660 | 0.020 |
Why?
|
| Vitamin E | 1 | 1995 | 874 | 0.020 |
Why?
|
| Depression | 1 | 2011 | 8240 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10486 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2013 | 440 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2010 | 157 | 0.020 |
Why?
|
| Patient Preference | 1 | 2018 | 947 | 0.020 |
Why?
|
| Adiposity | 1 | 2020 | 1895 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2010 | 128 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2012 | 221 | 0.020 |
Why?
|
| Telemedicine | 1 | 2008 | 3109 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 16051 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1998 | 2202 | 0.020 |
Why?
|
| Glutathione | 1 | 2012 | 589 | 0.020 |
Why?
|
| Respiration | 1 | 1996 | 1668 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 9528 | 0.020 |
Why?
|
| Decision Making | 1 | 2024 | 3952 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 17174 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 379 | 0.020 |
Why?
|
| Netherlands | 1 | 1994 | 2277 | 0.020 |
Why?
|
| Rabbits | 1 | 1996 | 4774 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2004 | 6434 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1997 | 1181 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 2734 | 0.020 |
Why?
|
| Awards and Prizes | 1 | 2013 | 365 | 0.020 |
Why?
|
| Autoanalysis | 1 | 2008 | 70 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1990 | 283 | 0.020 |
Why?
|
| Walking | 1 | 1996 | 1201 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2013 | 675 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2013 | 1866 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 1439 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2010 | 391 | 0.020 |
Why?
|
| Heart, Artificial | 1 | 2008 | 110 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22381 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 811 | 0.020 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2008 | 65 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2784 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 3110 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2013 | 1096 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2009 | 215 | 0.020 |
Why?
|
| Teaching | 1 | 1995 | 1171 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23652 | 0.020 |
Why?
|
| Maryland | 1 | 2007 | 278 | 0.020 |
Why?
|
| APACHE | 1 | 2007 | 268 | 0.020 |
Why?
|
| Psychometrics | 1 | 2017 | 3066 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 430 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5890 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 270 | 0.020 |
Why?
|
| Stents | 1 | 1998 | 3200 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 1992 | 965 | 0.020 |
Why?
|
| Lipoproteins | 3 | 1998 | 880 | 0.020 |
Why?
|
| Seafood | 1 | 2009 | 395 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 997 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 3414 | 0.020 |
Why?
|
| Fishes | 1 | 2009 | 606 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1994 | 6242 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 1931 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1627 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 1941 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2009 | 565 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1998 | 2297 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2008 | 900 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 746 | 0.020 |
Why?
|
| Mercury Radioisotopes | 1 | 1984 | 1 | 0.010 |
Why?
|
| Hordeolum | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 241 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 1376 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2008 | 917 | 0.010 |
Why?
|
| Astrocytes | 1 | 2012 | 1349 | 0.010 |
Why?
|
| Trachoma | 1 | 2004 | 19 | 0.010 |
Why?
|
| Chalazion | 1 | 2004 | 10 | 0.010 |
Why?
|
| Sympathetic Nervous System | 2 | 1997 | 521 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 2149 | 0.010 |
Why?
|
| Switzerland | 1 | 2005 | 323 | 0.010 |
Why?
|
| Blepharitis | 1 | 2004 | 35 | 0.010 |
Why?
|
| Vasodilation | 1 | 2008 | 967 | 0.010 |
Why?
|
| Massachusetts | 1 | 2017 | 8888 | 0.010 |
Why?
|
| Myocardial Reperfusion | 1 | 2005 | 339 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2014 | 1515 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1984 | 363 | 0.010 |
Why?
|
| Public Sector | 1 | 2005 | 266 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9375 | 0.010 |
Why?
|
| Exercise Tolerance | 2 | 1999 | 846 | 0.010 |
Why?
|
| Conjunctivitis | 1 | 2004 | 153 | 0.010 |
Why?
|
| Genotype | 2 | 2011 | 13048 | 0.010 |
Why?
|
| Macrophages | 1 | 1998 | 5800 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2009 | 914 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2008 | 5323 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 1990 | 1248 | 0.010 |
Why?
|
| Mice | 2 | 2006 | 82074 | 0.010 |
Why?
|
| Private Sector | 1 | 2005 | 396 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 2 | 1993 | 414 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 26394 | 0.010 |
Why?
|
| Information Systems | 2 | 1993 | 400 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 2003 | 408 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3411 | 0.010 |
Why?
|
| Oils | 1 | 2001 | 53 | 0.010 |
Why?
|
| Alanine Transaminase | 2 | 1993 | 606 | 0.010 |
Why?
|
| Benchmarking | 1 | 2007 | 1058 | 0.010 |
Why?
|
| Emulsions | 1 | 2001 | 152 | 0.010 |
Why?
|
| Compliance | 1 | 2000 | 100 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 1281 | 0.010 |
Why?
|
| Pulse | 1 | 2000 | 218 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 12252 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1984 | 2299 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2001 | 291 | 0.010 |
Why?
|
| Baroreflex | 1 | 2000 | 154 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2005 | 959 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1855 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2875 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 899 | 0.010 |
Why?
|
| Spleen | 1 | 1984 | 2294 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2005 | 2742 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1998 | 6982 | 0.010 |
Why?
|
| Leukotriene C4 | 1 | 1998 | 79 | 0.010 |
Why?
|
| Carbachol | 1 | 1998 | 223 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 1674 | 0.010 |
Why?
|
| Triage | 1 | 2004 | 997 | 0.010 |
Why?
|
| Biliary Tract Diseases | 1 | 1997 | 159 | 0.010 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 472 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2005 | 1876 | 0.010 |
Why?
|
| Denervation | 1 | 1997 | 265 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 325 | 0.010 |
Why?
|
| Schools | 1 | 2004 | 1498 | 0.010 |
Why?
|
| Sex Education | 1 | 1995 | 94 | 0.010 |
Why?
|
| Vagus Nerve | 1 | 1997 | 460 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1997 | 1104 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1995 | 269 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 3112 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2009 | 3431 | 0.010 |
Why?
|
| Bundle of His | 1 | 1992 | 102 | 0.010 |
Why?
|
| Lipids | 2 | 1993 | 3345 | 0.010 |
Why?
|
| Sexual Partners | 1 | 1997 | 807 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 366 | 0.010 |
Why?
|
| Folic Acid | 1 | 1998 | 1336 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1993 | 685 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 8090 | 0.010 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1997 | 668 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 6131 | 0.010 |
Why?
|
| Biological Factors | 1 | 1990 | 158 | 0.000 |
Why?
|
| Orthopedics | 1 | 1997 | 906 | 0.000 |
Why?
|
| Thrombin | 1 | 1990 | 600 | 0.000 |
Why?
|
| Health Surveys | 1 | 1997 | 4055 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1997 | 2660 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1995 | 2025 | 0.000 |
Why?
|
| Phospholipids | 1 | 1990 | 787 | 0.000 |
Why?
|
| Liposomes | 1 | 1990 | 792 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 7860 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1990 | 3102 | 0.000 |
Why?
|
| Liver Transplantation | 1 | 1995 | 2403 | 0.000 |
Why?
|
| Cell Communication | 1 | 1990 | 1660 | 0.000 |
Why?
|
| Health Personnel | 1 | 1995 | 3382 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1990 | 2820 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1990 | 3659 | 0.000 |
Why?
|
| Neutrophils | 1 | 1990 | 3785 | 0.000 |
Why?
|
| HIV Infections | 1 | 1997 | 17589 | 0.000 |
Why?
|